Current developments in the therapeutic potential of S-nitrosoglutathione, an endogenous NO-donor molecule

István Hornyák, E. Pankotai, L. Kiss, Z. Lacza

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Nitric oxide (NO) has a role in many physiological processes and its decreased concentration can lead to several pathophysiological events, therefore it is of considerable importance to find and to characterize suitable NO-donors for clinical use. S-nitrosothiols (RSNOs) are promising candidates for such therapeutics because these molecules do not appear to induce tolerance and were shown to be effective in several disease models. One of the main endogenous nitrosothiols is S-nitrosoglutathione (GSNO), which was tested as a therapeutic agent in 15 human investigations with good results. Despite the proven benefits of GSNO this molecule is not yet present in any pharmaceutical composition. The problem with the use of nitrosothiols is their fast and often unpredictable rate of decomposition in aqueous solutions. In this article we review current developments in the field which relate to the clinical applications of GSNO and other nitrosothiols in indications such as asthma, cystic fibrosis, embolization prevention or diabetic leg ulcers. The review focuses on the chemical and biological data which support the therapeutic use of GSNO and highlights areas where further research is needed.

Original languageEnglish
Pages (from-to)1368-1374
Number of pages7
JournalCurrent Pharmaceutical Biotechnology
Volume12
Issue number9
Publication statusPublished - Sep 2011

Fingerprint

S-Nitrosoglutathione
Nitric Oxide Donors
S-Nitrosothiols
Physiological Phenomena
Leg Ulcer
Therapeutic Uses
Cystic Fibrosis
Nitric Oxide
Asthma
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Diabetic neuropathy
  • GSNO
  • Nitrosothiols
  • Percutan transcutaneous carotid angioplasty
  • Platelet activation
  • S-nitrosoglutathione
  • Venous ulcer

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Biotechnology

Cite this

@article{44a138d1c6e6463c9379fe301f0206db,
title = "Current developments in the therapeutic potential of S-nitrosoglutathione, an endogenous NO-donor molecule",
abstract = "Nitric oxide (NO) has a role in many physiological processes and its decreased concentration can lead to several pathophysiological events, therefore it is of considerable importance to find and to characterize suitable NO-donors for clinical use. S-nitrosothiols (RSNOs) are promising candidates for such therapeutics because these molecules do not appear to induce tolerance and were shown to be effective in several disease models. One of the main endogenous nitrosothiols is S-nitrosoglutathione (GSNO), which was tested as a therapeutic agent in 15 human investigations with good results. Despite the proven benefits of GSNO this molecule is not yet present in any pharmaceutical composition. The problem with the use of nitrosothiols is their fast and often unpredictable rate of decomposition in aqueous solutions. In this article we review current developments in the field which relate to the clinical applications of GSNO and other nitrosothiols in indications such as asthma, cystic fibrosis, embolization prevention or diabetic leg ulcers. The review focuses on the chemical and biological data which support the therapeutic use of GSNO and highlights areas where further research is needed.",
keywords = "Diabetic neuropathy, GSNO, Nitrosothiols, Percutan transcutaneous carotid angioplasty, Platelet activation, S-nitrosoglutathione, Venous ulcer",
author = "Istv{\'a}n Horny{\'a}k and E. Pankotai and L. Kiss and Z. Lacza",
year = "2011",
month = "9",
language = "English",
volume = "12",
pages = "1368--1374",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Current developments in the therapeutic potential of S-nitrosoglutathione, an endogenous NO-donor molecule

AU - Hornyák, István

AU - Pankotai, E.

AU - Kiss, L.

AU - Lacza, Z.

PY - 2011/9

Y1 - 2011/9

N2 - Nitric oxide (NO) has a role in many physiological processes and its decreased concentration can lead to several pathophysiological events, therefore it is of considerable importance to find and to characterize suitable NO-donors for clinical use. S-nitrosothiols (RSNOs) are promising candidates for such therapeutics because these molecules do not appear to induce tolerance and were shown to be effective in several disease models. One of the main endogenous nitrosothiols is S-nitrosoglutathione (GSNO), which was tested as a therapeutic agent in 15 human investigations with good results. Despite the proven benefits of GSNO this molecule is not yet present in any pharmaceutical composition. The problem with the use of nitrosothiols is their fast and often unpredictable rate of decomposition in aqueous solutions. In this article we review current developments in the field which relate to the clinical applications of GSNO and other nitrosothiols in indications such as asthma, cystic fibrosis, embolization prevention or diabetic leg ulcers. The review focuses on the chemical and biological data which support the therapeutic use of GSNO and highlights areas where further research is needed.

AB - Nitric oxide (NO) has a role in many physiological processes and its decreased concentration can lead to several pathophysiological events, therefore it is of considerable importance to find and to characterize suitable NO-donors for clinical use. S-nitrosothiols (RSNOs) are promising candidates for such therapeutics because these molecules do not appear to induce tolerance and were shown to be effective in several disease models. One of the main endogenous nitrosothiols is S-nitrosoglutathione (GSNO), which was tested as a therapeutic agent in 15 human investigations with good results. Despite the proven benefits of GSNO this molecule is not yet present in any pharmaceutical composition. The problem with the use of nitrosothiols is their fast and often unpredictable rate of decomposition in aqueous solutions. In this article we review current developments in the field which relate to the clinical applications of GSNO and other nitrosothiols in indications such as asthma, cystic fibrosis, embolization prevention or diabetic leg ulcers. The review focuses on the chemical and biological data which support the therapeutic use of GSNO and highlights areas where further research is needed.

KW - Diabetic neuropathy

KW - GSNO

KW - Nitrosothiols

KW - Percutan transcutaneous carotid angioplasty

KW - Platelet activation

KW - S-nitrosoglutathione

KW - Venous ulcer

UR - http://www.scopus.com/inward/record.url?scp=80052216643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052216643&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1368

EP - 1374

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 9

ER -